PL1651248T3 - Doustnie dawkowana kompozycja farmaceutyczna zawierająca środek dostarczający w postaci mikronizowanej - Google Patents

Doustnie dawkowana kompozycja farmaceutyczna zawierająca środek dostarczający w postaci mikronizowanej

Info

Publication number
PL1651248T3
PL1651248T3 PL04740863T PL04740863T PL1651248T3 PL 1651248 T3 PL1651248 T3 PL 1651248T3 PL 04740863 T PL04740863 T PL 04740863T PL 04740863 T PL04740863 T PL 04740863T PL 1651248 T3 PL1651248 T3 PL 1651248T3
Authority
PL
Poland
Prior art keywords
pharmaceutical compositions
delivery agent
pharmacologically active
micronized form
orally dosed
Prior art date
Application number
PL04740863T
Other languages
English (en)
Inventor
Shoufeng Li
Anasuya Ashok Ghosh
Simon David Bateman
Moise Azria
Alan Edward Royce
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL1651248T3 publication Critical patent/PL1651248T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Permanent Magnet Type Synchronous Machine (AREA)
PL04740863T 2003-07-11 2004-07-09 Doustnie dawkowana kompozycja farmaceutyczna zawierająca środek dostarczający w postaci mikronizowanej PL1651248T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48649503P 2003-07-11 2003-07-11
EP04740863A EP1651248B1 (en) 2003-07-11 2004-07-09 Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
PCT/EP2004/007584 WO2005004900A1 (en) 2003-07-11 2004-07-09 Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

Publications (1)

Publication Number Publication Date
PL1651248T3 true PL1651248T3 (pl) 2010-02-26

Family

ID=34062133

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04740863T PL1651248T3 (pl) 2003-07-11 2004-07-09 Doustnie dawkowana kompozycja farmaceutyczna zawierająca środek dostarczający w postaci mikronizowanej

Country Status (14)

Country Link
US (3) US20070065505A1 (pl)
EP (1) EP1651248B1 (pl)
JP (1) JP5032844B2 (pl)
CN (1) CN1809377B (pl)
AT (1) ATE442158T1 (pl)
AU (1) AU2004255458B2 (pl)
BR (1) BRPI0412458A (pl)
CA (1) CA2529604C (pl)
DE (1) DE602004023093D1 (pl)
ES (1) ES2330638T3 (pl)
MX (1) MXPA06000446A (pl)
PL (1) PL1651248T3 (pl)
PT (1) PT1651248E (pl)
WO (1) WO2005004900A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04001418A (es) * 2001-08-17 2004-05-27 Novartis Ag Acido n-(5-clorosalociloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides.
US20060078623A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
CN101627011A (zh) * 2005-09-19 2010-01-13 爱密斯菲尔科技公司 N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形
GB0522566D0 (en) 2005-11-04 2005-12-14 Novartis Ag Organic compounds
CA2661521C (en) 2006-08-31 2016-04-12 Novartis Ag Pharmaceutical compositions comprising hgh for oral delivery
WO2008039351A2 (en) * 2006-09-22 2008-04-03 Novartis Ag Method of manufacturing tablets containing pharmacologically active agents
PL2215047T3 (pl) * 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
AR080292A1 (es) * 2010-02-24 2012-03-28 Emisphere Tech Inc Metodo para normalizar en forma rapida los niveles de vitamina b12 en un paciente que tiene deficiencia de vitamina b12 y un nivel promedio de vitamina b12 por debajo de 350 pg/ml
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
PL3542790T3 (pl) 2012-03-22 2024-02-26 Novo Nordisk A/S Kompozycje zawierające substancję dostarczającą i ich przygotowanie
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
CN104095828A (zh) * 2014-07-29 2014-10-15 中国药科大学 一种降钙素口服肠溶组合物及其制备方法
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
CR20230308A (es) 2020-12-11 2023-09-08 Civi Biopharma Inc Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
PE20240640A1 (es) 2021-04-22 2024-04-04 Civi Biopharma Inc Administracion oral de oligonucleotidos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US6413546B1 (en) * 1999-03-18 2002-07-02 Indena, S.P.A. Tablets incorporating isoflavone plant extracts and methods of manufacturing them
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6544553B1 (en) * 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
SK285128B6 (sk) * 1999-12-28 2006-07-07 Zentiva, A. S. Liečivý prípravok s riadeným uvoľňovaním obsahujúci tramadol hydrochlorid a spôsob jeho prípravy
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Also Published As

Publication number Publication date
BRPI0412458A (pt) 2006-10-17
US20080234179A1 (en) 2008-09-25
ATE442158T1 (de) 2009-09-15
WO2005004900A1 (en) 2005-01-20
CA2529604A1 (en) 2005-01-20
EP1651248B1 (en) 2009-09-09
HK1089950A1 (en) 2006-12-15
AU2004255458A1 (en) 2005-01-20
EP1651248A1 (en) 2006-05-03
JP5032844B2 (ja) 2012-09-26
ES2330638T3 (es) 2009-12-14
AU2004255458B2 (en) 2007-09-13
US8435946B2 (en) 2013-05-07
MXPA06000446A (es) 2006-04-07
CA2529604C (en) 2012-05-08
CN1809377B (zh) 2010-08-04
DE602004023093D1 (de) 2009-10-22
US8748383B2 (en) 2014-06-10
JP2009513528A (ja) 2009-04-02
US20130230593A1 (en) 2013-09-05
US20070065505A1 (en) 2007-03-22
CN1809377A (zh) 2006-07-26
PT1651248E (pt) 2009-11-10

Similar Documents

Publication Publication Date Title
IL155992A0 (en) Pharmaceutical compositions for the oral delivery of pharmacologically active agents
PT1651248E (pt) Composições farmacêuticas para dose oral compreendendo um agente de administração na forma micronizada
WO2008021088A3 (en) Salicylanilides enhance oral delivery of therapeutic peptides
GEP20074231B (en) Calcitonin gene related peptide receptor antagonists
TWI366460B (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
GEP20074047B (en) Pramipexole once-daily dosage form
AR033711A1 (es) Composiciones farmaceuticas
TW200517106A (en) Sustained release pharmaceutical compositions
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
ZA200709788B (en) Cannabinold active pharmaceutical ingredient for Improved dosage forms
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
IL157540A0 (en) N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof
EP1755633A4 (en) ORAL ADMINISTRATION OF PEPTIDE PHARMACEUTICAL COMPOSITIONS
EA200600953A1 (ru) Дозированные формы торсемида пролонгированного высвобождения
WO2007011958A3 (en) Intraoral dosage forms of glucagon
TW200638927A (en) Bambuterol and integrin inhibitor combination
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
WO2005062722A3 (en) Fexofenadine containing pharmaceutical formulation
WO2007035816A3 (en) Paroxetine compositions
TW200833375A (en) Pharmaceutical compositions
PL1653963T3 (pl) Donosowa kompozycja farmaceutyczna pirybedilu
HU0500270D0 (en) Pharmacologically active peptide derivatives, process for their preparation and pharmaceutical compositions containing the same
TNSN06299A1 (en) Oral matrix formulations comprising licarbazepine
SI1471890T1 (sl) Farmacevtska dozirna oblika za dajanje v sluznico